Curing metastatic cancer: lessons from testicular germ-cell tumours
- 1 July 2003
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 3 (7) , 517-525
- https://doi.org/10.1038/nrc1120
Abstract
Most metastatic cancers are fatal. More than 80% of patients with metastatic testicular germ-cell tumours (TGCTs), however, can be cured using cisplatin-based combination chemotherapy. Why are TGCTs more sensitive to chemotherapeutics than most other tumour types? Answers to this question could lead to new treatments for metastatic cancers.Keywords
This publication has 52 references indexed in Scilit:
- HeLa cells 50 years on: the good, the bad and the uglyNature Reviews Cancer, 2002
- Curing metastatic testicular cancerProceedings of the National Academy of Sciences, 2002
- Estimating the world cancer burden: Globocan 2000International Journal of Cancer, 2001
- Human cancer cell lines: fact and fantasyNature Reviews Molecular Cell Biology, 2000
- Testicular Germ-Cell CancerNew England Journal of Medicine, 1997
- Apoptosis of human seminoma cells upon disruption of their microenvironmentBritish Journal of Cancer, 1996
- Differential Sensitivities to Gamma Radiation of Human Bladder and Testicular Tumour Cell LinesInternational Journal of Radiation Biology, 1988
- Effects of CIS‐platinum on embryonal carcinoma cell lines in vitroInternational Journal of Cancer, 1984
- Cis-Diamminedichloroplatinum, Vinblastine, and Bleomycin Combination Chemotherapy in Disseminated Testicular CancerAnnals of Internal Medicine, 1977
- Combination chemotherapy in germinal cell tumorsCancer Treatment Reviews, 1976